I wonder if this will become relevant with XMRV.
"Dramatic resolution of bone metastases occurred in 85% of patients with castration-resistant prostate cancer treated with a wide-spectrum tyrosine kinase inhibitor, according to preliminary study data."
"the bone effects of cabozantinib are not limited to castration-resistant prostate cancer. Benefits have also been observed in breast cancer, melanoma, thyroid cancer, and renal cell cancer."
http://www.medpagetoday.com/Meeting...eadlines&utm_source=WC&em=leelaplay@gmail.com
"Dramatic resolution of bone metastases occurred in 85% of patients with castration-resistant prostate cancer treated with a wide-spectrum tyrosine kinase inhibitor, according to preliminary study data."
"the bone effects of cabozantinib are not limited to castration-resistant prostate cancer. Benefits have also been observed in breast cancer, melanoma, thyroid cancer, and renal cell cancer."
http://www.medpagetoday.com/Meeting...eadlines&utm_source=WC&em=leelaplay@gmail.com